Company / PP&E (Net)
Rapport Therapeutics, Inc. PP&E (Net) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.5M
FY2024
5-year range
$1.9M / $3.5M
FY2023-FY2024
Trend
+84.2%
vs FY2023
Sector context
#120 of 193
Health Care
What the data says
At $4M, Rapport Therapeutics, Inc.'s pp&e (net) ranks #120 of 193 in the Health Care sector.
Based on SEC 10-K filings.
$4M in FY2024.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#120 of 193 in Health CareTop 62% of 193This company $3.5M Sector average $777.6M
▼
-99.5% below sector average
Key checks
Key Insights
- In FY2024, pp&e (net) increased 84.2% year-over-year.
- Ranks #120 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.5M | +84.2% |
| FY2023 | $1.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026